These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32697437)

  • 21. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.
    Chen Y; Balthasar JP
    AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.
    Haraya K; Tachibana T; Nanami M; Ishigai M
    Xenobiotica; 2014 Dec; 44(12):1127-34. PubMed ID: 25030041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.
    Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P
    J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies.
    Roopenian DC; Christianson GJ; Sproule TJ
    Methods Mol Biol; 2010; 602():93-104. PubMed ID: 20012394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Human Pharmacokinetics Profile of Monoclonal Antibody Using hFcRn Transgenic Mouse Model.
    Nakamura G; Ozeki K; Takesue H; Tabo M; Hosoya KI
    Biol Pharm Bull; 2021; 44(3):389-395. PubMed ID: 33642546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.
    Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP
    J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An
    Chung S; Nguyen V; Lin YL; Lafrance-Vanasse J; Scales SJ; Lin K; Deng R; Williams K; Sperinde G; Li JJ; Zheng K; Sukumaran S; Tesar D; Ernst JA; Fischer S; Lazar GA; Prabhu S; Song A
    MAbs; 2019 Jul; 11(5):942-955. PubMed ID: 30982394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice.
    Naoi S; Yamane M; Nemoto T; Kato M; Saito R; Tachibana T
    Drug Metab Pharmacokinet; 2023 Dec; 53():100506. PubMed ID: 38029470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.
    Fan YY; Avery LB; Wang M; O'Hara DM; Leung S; Neubert H
    MAbs; 2016 Jul; 8(5):848-53. PubMed ID: 27104806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fc engineered anti-virus therapeutic human IgG
    Park SA; Lee Y; Hwang H; Lee JH; Kang YJ; Kim Y; Jin C; An HJ; Oh YJ; Hinterdorfer P; Kim E; Choi S; Ko K
    Biotechnol J; 2024 Mar; 19(3):e2300552. PubMed ID: 38528347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
    Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
    MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.
    Guilleminault L; Azzopardi N; Arnoult C; Sobilo J; Hervé V; Montharu J; Guillon A; Andres C; Herault O; Le Pape A; Diot P; Lemarié E; Paintaud G; Gouilleux-Gruart V; Heuzé-Vourc'h N
    J Control Release; 2014 Dec; 196():344-54. PubMed ID: 25451545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework.
    Ollier R; Fuchs A; Gauye F; Piorkowska K; Menant S; Ratnam M; Montanari P; Guilhot F; Phillipe D; Audrain M; Egesipe AL; Névoltris D; Seredenina T; Pfeifer A; Kosco-Vilbois M; Afroz T
    MAbs; 2023; 15(1):2232087. PubMed ID: 37408314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.